Acumen Pharmaceuticals Inc ABOS
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if ABOS is a good fit for your portfolio.
News
-
Acumen Pharmaceuticals Presents First Comprehensive Clinical and Biomarker Data for Sabirnetug (ACU193) at American Academy of Neurology 2024 Annual Meeting
-
Acumen Pharmaceuticals Collaborates with Lonza to Advance Sabirnetug for the Treatment of Alzheimer’s Disease
-
Acumen Pharmaceuticals Reports Financial Results for the Year Ended December 31, 2023 and Business Highlights
-
Acumen Pharmaceuticals to Present Deeper Insights, Including Fluid Biomarker Data for Sabirnetug (ACU193), During Emerging Science Session at the American Academy of Neurology Annual Meeting
-
Acumen Pharmaceuticals to Report Fourth Quarter and Year-End 2023 Financial Results on March 26, 2024
-
Acumen Pharmaceuticals to Participate in the Stifel 2024 CNS Days
-
Acumen Pharmaceuticals Presents Sabirnetug (ACU193) Fluid Biomarker and Target Engagement Analyses from Phase 1 INTERCEPT-AD Study in Early Alzheimer’s at the AD/PD™ 2024 Annual Meeting
-
Acumen Pharmaceuticals to Present Sabirnetug (ACU193) Fluid Biomarker and Target Engagement Analyses from Phase 1 INTERCEPT-AD Study in Early Alzheimer’s at the AD/PD™ 2024 Annual Meeting
Trading Information
- Previous Close Price
- $3.16
- Day Range
- $3.10–3.30
- 52-Week Range
- $1.81–11.31
- Bid/Ask
- $3.10 / $3.29
- Market Cap
- $189.25 Mil
- Volume/Avg
- 307,602 / 354,285
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 52
- Website
- https://www.acumenpharm.com
Comparables
Valuation
Metric
|
ABOS
|
CRNX
|
ACLX
|
---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 0.69 | 5.44 | 5.87 |
Price/Sales | — | 622.39 | 23.74 |
Price/Cash Flow | — | — | — |
Price/Earnings
ABOS
CRNX
ACLX
Financial Strength
Metric
|
ABOS
|
CRNX
|
ACLX
|
---|---|---|---|
Quick Ratio | 18.79 | 12.92 | 5.94 |
Current Ratio | 19.01 | 13.07 | 6.06 |
Interest Coverage | −107.71 | — | −23.39 |
Quick Ratio
ABOS
CRNX
ACLX
Profitability
Metric
|
ABOS
|
CRNX
|
ACLX
|
---|---|---|---|
Return on Assets (Normalized) | −19.37% | −38.81% | −6.26% |
Return on Equity (Normalized) | −20.70% | −44.79% | −12.08% |
Return on Invested Capital (Normalized) | −24.75% | −45.62% | −13.11% |
Return on Assets
ABOS
CRNX
ACLX
Biotechnology Industry Comparables
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Rfrbbdhsr | Hzz | $550.4 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Dgcsqfgz | Tsqhxb | $101.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Gtnzwjmnk | Whtxj | $98.1 Bil | |
MRNA
| Moderna Inc | Qhmscnfh | Lkjg | $39.1 Bil | |
ARGX
| argenx SE ADR | Rnfdrfrj | Ydb | $21.7 Bil | |
BNTX
| BioNTech SE ADR | Xjtzcdyzf | Dbnz | $20.8 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Zfttpxth | Cxpyrty | $18.4 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Dtblncfqk | Nwgwplm | $17.1 Bil | |
RPRX
| Royalty Pharma PLC Class A | Yqpsfzygt | Dhhjxy | $12.5 Bil | |
INCY
| Incyte Corp | Lymsccyv | Mjlmj | $11.9 Bil |